ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Impact of radiotherapy on quality of life reported by elderly patients.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives and purposesTo determine the impact of radical radiotherapy (RT) treatment on the quality of life reported by elderly patients. MATERIALS AND
methodsA prospective multicenter study was conducted in 8 national centers. Patients over 70 years old who had an indication for radical RT were included. All patients were initially assessed with the Geriatric-8 (G8) scale, ECOG PS, Nutriscore, SARC_F (sarcopenia questionnaire), and completed two patient-reported outcomes measure (PROMs) questionnaires: the EORTC_QLQ_C30 and the EORTC_ELD_14 quality of life (QoL), at baseline, at the end of RT, and 3 months later.
resultsA total of 156 patients with a mean age of 77 years (range 70-93) were included. The characteristics of the patients are as follows: 65.4% are men, 45.5% have prostate cancer, 20% breast cancer, and 12.2% lung cancer. The baseline PROMs show general health status of patients >70 years with some deterioration (73.5 ± 20.3). Patients also present deterioration in physical function (85.29 ± 19.94), emotional function (81.02 ± 21.28), and maintenance of purpose (70.94 ± 30.5), and the most frequent baseline symptoms are constipation, fatigue, insomnia, worries about others, future worries, disease burden, and joint stiffness. The prognostic factors that increase the risk of these alterations are ECOG PS >1, female sex, diabetes, dyslipidemia, pulmonary pathology, cognitive impairment, and especially the risk of sarcopenia. When comparing PROMs at the beginning and at the end of oncological treatment, a significant deterioration in role function (89.86 vs. 85.62, p = 0.004) and an increase in fatigue (19.89 vs. 25.78, p = 0.002) are observed. While the PROMs at 3 months show improvement in all functions and symptoms, statistically significant improvement was only found in emotional function (84 vs. 89.26, p = 0.000), fatigue (25.87 vs. 20.4, p = 0.001), loss of appetite (12.75 vs. 6.7, p = 0.003), and maintenance of purpose (68 vs. 73.6, p = 0.14).
conclusionOlder patients, due to their comorbidities, already have alterations in QoL, with sarcopenia being an important factor. Cancer treatment further deteriorates QoL in a significant way, role function and fatigue, but 3 months after the treatment, improvements in QoL, significantly emotional function, fatigue, loss of appetite and maintenance of purpose are observed.
Indexed as
Identifiers
42068504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.